• 1
    Agteresch HJ, Dagnelie PC, van der Gaast A, et al. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92: 321328.
  • 2
    Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in operable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000; 83: 447453.
  • 3
    Fossa SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a Phase III study of the European Organization for Research and Treatment of cancer. J Clin Oncol. 2001; 19: 6271.
  • 4
    Hultborn R, Gundersen S, Ryden S, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res. 1999; 19: 33833392.
  • 5
    Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol. 1997; 34 (suppl 2): 412.
  • 6
    Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist. 2000; 5: 353360.
  • 7
    Cella D, Peterman A, Passik S, Jacobsen P, Breitbart W. Progress toward guidelines for the management of fatigue. Oncology. 1998; 12: 369377.
  • 8
    Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res. 1994; 3: 183189.
  • 9
    Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999; 91: 16161634.
  • 10
    Miller CB, Jones RJ, Piantadosi S, Abeloff MD, Spivak JL. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990; 322: 16891692.
  • 11
    Auer J, Oliver DO, Winearls CG. The quality of life of dialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol Suppl. 1990; 131: 6165.
  • 12
    Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 1996; 7: 763773.
  • 13
    Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ. 1990; 300: 573578.
  • 14
    Churchill DN, Muirhead N, Goldstein M, et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol. 1995; 43: 184188.
  • 15
    Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA. 1990; 263: 825830.
  • 16
    Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeithofer J, Schneider B. Improvement of brain function in haemodialysis patients treated with erythropoietin. Kidney Int. 1990; 38: 17.
  • 17
    Harris DC, Chapman JR, Stewart JH. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. Aust N Z J Med. 1991; 21: 693700.
  • 18
    Iseki K, Nishime K, Uehara H, et al. Increased risk of cardiovascular disease with erythropoietin in chronic dialysis patients. Nephron. 1996; 72: 3036.
  • 19
    Laupacis A, Wong C, Churchill D. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trials. 1991; 12: 168S179S.
  • 20
    Lundin AP, Akerman MJH, Chesler RM, et al. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron. 1991; 58: 315319.
  • 21
    Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int. 1988; 34: 525528.
  • 22
    Moreno F, Aracil FJ, Pérez R, Valderrábano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis. 1996; 27: 548556.
  • 23
    Nissenson AR, Pickett JL, Theberge DC, Brown WS, Schweitzer SV. Brain function is better in hemodialysis patients when hematocrit is normalized with erythropoietin [abstract]. J Am Soc Nephrol. 1996; 7: 1459.
  • 24
    Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995; 25: 548554.
  • 25
    The US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 1991;18: 5059.
  • 26
    Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 1993; 29A (suppl 2): S2S8.
  • 27
    Case DC Jr., Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst. 1993; 85: 801806.
  • 28
    Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998; 16: 34123425.
  • 29
    Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997; 15: 12181234.
  • 30
    Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001; 19: 28752882.
  • 31
    Leitgeb C, Pecherstorfer M, Fritz E, Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 1994; 73: 25352542.
  • 32
    Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19: 28652874.
  • 33
    Rose E, Rai K, Revicki D, Brown R, Reblando J, and the EPO in Anemia of CLL Study Group. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO)[abstract]. Blood. 1994; 84(suppl 1): 526A.
  • 34
    Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002; 3: 180190.
  • 35
    Eschbach JW. The future of r-HuEPO. Nephrol Dial Transplant. 1995; 10 (suppl 2): 96109.
  • 36
    Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997; 34 (suppl 2): 1319.
  • 37
    Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997; 13: 6374.
  • 38
    McGuigan JR, Moyer C, Harris FH. Managerial economics. 7th ed. St Paul: West Publishing Company, 1996.
  • 39
    Heckman JJ. Sample selection bias as a specification error. Econometrica. 1979; 47: 153161.
  • 40
    Crown B, Obenchain R, Englehart L, Lair T, Buesching D, Croghan T. The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilization. Stat Med. 1998; 17: 19431958.
  • 41
    Spilker B. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1996
  • 42
    Serland RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61: 277284.
  • 43
    Leung SF, Yu S. On the choice between sample selection and two-part models. J Econometrics. 1996; 72: 197229.